Arcadia Biosciences Inc (RKDA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Arcadia Biosciences Inc stock (RKDA) is currently trading at $1.70. Arcadia Biosciences Inc PS ratio (Price-to-Sales) is 0.72. Analyst consensus price target for RKDA is $12.00. WallStSmart rates RKDA as Sell.
- RKDA PE ratio analysis and historical PE chart
- RKDA PS ratio (Price-to-Sales) history and trend
- RKDA intrinsic value — DCF, Graham Number, EPV models
- RKDA stock price prediction 2025 2026 2027 2028 2029 2030
- RKDA fair value vs current price
- RKDA insider transactions and insider buying
- Is RKDA undervalued or overvalued?
- Arcadia Biosciences Inc financial analysis — revenue, earnings, cash flow
- RKDA Piotroski F-Score and Altman Z-Score
- RKDA analyst price target and Smart Rating
Arcadia Biosciences Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Arcadia Biosciences Inc (RKDA) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, eps growth. Concerns around market cap and peg ratio. Mixed signals suggest waiting for clearer direction before acting.
Arcadia Biosciences Inc (RKDA) Key Strengths (3)
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
Strong earnings growth at 28.50% per year
Supporting Valuation Data
Arcadia Biosciences Inc (RKDA) Areas to Watch (7)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Losing money on operations
Revenue declining -15.30%, a shrinking business
Company is losing money with a negative profit margin
Very low institutional interest at 1.15%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Arcadia Biosciences Inc (RKDA) Detailed Analysis Report
Overall Assessment
This company scores 37/100 in our Smart Analysis, earning a F grade. Out of 10 metrics analyzed, 3 register as strengths (avg 9.3/10) while 7 fall into concern territory (avg 0.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book, EPS Growth. Valuation metrics including Price/Sales (0.72), Price/Book (0.55) suggest the stock is attractively priced. Growth metrics are encouraging with EPS Growth at 28.50%.
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Operating Margin. Some valuation metrics including PEG Ratio (N/A) suggest expensive pricing. Growth concerns include Revenue Growth at -15.30%, which may limit upside. Profitability pressure is visible in Return on Equity at -64.60%, Operating Margin at -88.50%, Profit Margin at -98.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -64.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -15.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
RKDA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
RKDA's Price-to-Sales ratio of 0.72x trades at a deep discount to its historical average of 1.84x (37th percentile). The current valuation is 93% below its historical high of 10.32x set in Mar 2018, and 1095% above its historical low of 0.06x in Feb 2023. Over the past 12 months, the PS ratio has compressed from ~1.0x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Arcadia Biosciences Inc (RKDA) · CONSUMER DEFENSIVE › PACKAGED FOODS
The Big Picture
Arcadia Biosciences Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 5M with 15% decline year-over-year. The company is currently unprofitable, posting a -98.0% profit margin.
Key Findings
Revenue contracted 15% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -98.0% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor PACKAGED FOODS industry trends, competitive moves, and regulatory changes that could impact Arcadia Biosciences Inc.
Bottom Line
Arcadia Biosciences Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Arcadia Biosciences Inc(RKDA)
NASDAQ
CONSUMER DEFENSIVE
PACKAGED FOODS
USA
Arcadia Biosciences, Inc. is dedicated to developing various crop productivity traits primarily in hemp, wheat, and soybeans. The company is headquartered in Davis, California.